Key Points for Quality Research and Compliance Management of Recombinant Protein Biological Products

Quality Attribute Framework for Recombinant Protein Biological Products

Recombinant protein biological products have relatively complex structures, and their quality attributes generally include primary structure, higher-order structure, post-translational modifications, charge variants, aggregates, and degradation products. Because the manufacturing process involves live-cell expression, multi-step purification, and formulation processing, final release testing alone is insufficient to fully reflect product quality; process control and stability studies must be combined for comprehensive evaluation. Generally, a list of critical quality attributes should be established early in development to clarify which attributes are related to biological activity, immunogenicity risk, or stability, and to guide process development and analytical method selection.

Common Analytical Methods and Quality Control Strategies

Quality studies commonly use liquid chromatography, capillary electrophoresis, mass spectrometry, spectroscopy, and immunological methods. Molecular weight, peptide mapping, glycosylation profiles, charge heterogeneity, aggregate content, and host cell residual proteins are common test items. Glycoforms produced by different expression systems may differ, and glycan profile analysis is needed to assess batch-to-batch consistency. For aggregates and particulates, techniques such as size exclusion chromatography, dynamic light scattering, or microflow imaging are recommended for characterization. Analytical methods must undergo suitability confirmation or validation to demonstrate that their specificity, precision, and linear range meet the intended use.

Process Control and Data Integrity

Key parameters in upstream culture and downstream purification should be incorporated into the process control system, including temperature, pH, chromatography loading, elution conditions, and viral inactivation steps. Changes in raw materials and consumables may introduce new impurities or affect protein stability, and change risk assessments should be conducted. Data integrity is an important component of the quality system; electronic records, audit trails, and backup and recovery must comply with the general requirements of current Good Manufacturing Practice. Analytical data should be traceable and auditable to ensure an complete and reliable data chain from research and development to commercial batches.

Compliance and Risk Management Orientation

The development of recombinant protein biological products can refer to the relevant general chapters of the Chinese Pharmacopoeia, the ICH Q5 series, and quality risk management principles to establish a quality management system spanning the lifecycle. Stability studies should cover storage, transportation, and clinical use conditions, with attention to the potential effects of freeze-thaw, light exposure, and shaking on product quality. For biosimilars, quality comparison studies with the reference product are also required, but specific similarity conclusions should be based on systematic analytical data and risk assessment, and should not be judged simply by a single indicator. Through continuous quality research and risk control, recombinant protein biological products can achieve stable, traceable development and supply within a compliant framework.